• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Clearside Biomedical Inc.

    5/15/25 4:15:46 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSD alert in real time by email
    S-8 1 clsd-20250515.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on May 15, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________________________________

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    _____________________________________

     

    Clearside Biomedical, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

     

    45-2437375

    (State or other jurisdiction of Incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     

    900 North Point Parkway, Suite 200

    Alpharetta, Georgia 30005

    _____________________________________

    (Address of principal executive offices) (Zip code)

     

    2016 Equity Incentive Plan

    _____________________________________

    (Full title of the plan)

    George Lasezkay, Pharm.D., J.D.

    President and Chief Executive Officer

    Clearside Biomedical, Inc.

    900 North Point Parkway, Suite 200

    Alpharetta, Georgia 30005

    (678) 270-3631

    _____________________________________

     

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copies to:

     

    Mark Ballantyne

    Asheley Walker
    Cooley LLP
    One Freedom Square, Reston Town Center

    11951 Freedom Drive
    Reston, VA 20190
    (703) 456-8000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

     

    Large accelerated filer

     

    

     

     

    Accelerated filer

     

    

    Non-accelerated filer

     

    

     

     

    Smaller reporting company

     

    

     

     

     

     

     

    Emerging growth company

     

    

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     


     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by Clearside Biomedical, Inc., a Delaware corporation (the “Registrant”), pursuant to General Instruction E to Form S-8, to register 3,063,135 additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), to be issued pursuant to the Registrant’s 2016 Equity Incentive Plan (the “2016 EIP”). In accordance with such instruction, the Registrant hereby incorporates herein by reference the prior Registration Statements on Form S-8 filed by the Registrant with respect to the 2016 EIP on May 10, 2024 (File No. 333-279334), May 12, 2023 (File No. 333-271877), May 12, 2022 (File No. 333-264885), May 17, 2021 (File No. 333-256212), May 8, 2020 (File No. 333-238133), May 10, 2019 (File No. 333-231383), May 10, 2018 (File No. 333-224826), March 16, 2017 (File No. 333-216750) and June 14, 2016 (File No. 333-212014), together with all exhibits filed therewith or incorporated therein by reference.

     


     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 8. EXHIBITS.

     

    Exhibit Number

    Description

    4.1(1)

    Amended and Restated Certificate of Incorporation, as currently in effect.

    4.2(2)

    Certificate of Amendment to Amended and Restated Certificate of Incorporation, as currently in effect.

    4.3(3)

    Amended and Restated Bylaws, as currently in effect.

    4.4(4)

    Specimen stock certificate evidencing shares of Common Stock.

    4.5(5)

    2016 Equity Incentive Plan.

    4.6(6)

    Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan.

    4.7(7)

    Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2016 Equity Incentive Plan.

    5.1

    Opinion of Cooley LLP.

    23.1

    Consent of Ernst & Young LLP, independent registered public accounting firm.

    23.2

    Consent of Cooley LLP (included in Exhibit 5.1).

    24.1

    Power of Attorney (included on the signature page of this Form S-8).

    107

    Filing Fee Table.

     

    (1) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on June 7, 2016, and incorporated by reference herein.

    (2) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on June 23, 2022, and incorporated by reference herein.

    (3) Previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on June 7, 2016, and incorporated by reference herein.

    (4) Previously filed as Exhibit 4.1 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016, and incorporated by reference herein.

    (5) Previously filed as Exhibit 4.7 to the Registrant’s Registration Statement on Form S-8 (File No. 333-212014), filed with the Commission on June 14, 2016, and incorporated by reference herein.

    (6) Previously filed as Exhibit 10.7 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016, and incorporated by reference herein.

    (7) Previously filed as Exhibit 10.8 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016, and incorporated by reference herein.

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Alpharetta, State of Georgia, on this 15th day of May, 2025.

     

     

     

     

     

     

     

     

    Clearside Biomedical, Inc.

     

     

    By:

    /s/ George Lasezkay, Pharm.D., J.D.

     

     

     

     

    George Lasezkay, Pharm.D., J.D.

     

     

     

     

    President and Chief Executive Officer

     

     

     


     

    POWER OF ATTORNEY

    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints George Lasezkay and Charles A. Deignan, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ George Lasezkay, Pharm.D., J.D.

    George Lasezkay, Pharm.D., J.D.

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    May 15, 2025

     

     

     

    /s/ Charles A. Deignan

    Charles A. Deignan

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

    May 15, 2025

     

     

     

    /s/ Anthony S. Gibney

    Anthony S. Gibney

    Director

    May 15, 2025

     

     

     

    /s/ Richard Croarkin

    Richard Croarkin

    Director

    May 15, 2025

     

     

     

    /s/ Jeffrey L. Edwards

    Jeffrey L. Edwards

    Director

    May 15, 2025

     

     

     

     

     

     

    /s/ William D. Humphries

    William D. Humphries

    Director

    May 15, 2025

     

     

     

    /s/ Nancy J. Hutson

    Nancy J. Hutson

    Director

    May 15, 2025

     

     

     

    /s/ Christy L. Shaffer, Ph.D.

    Christy L. Shaffer, Ph.D.

    Director

    May 15, 2025

     

     

     

    /s/ Clay B. Thorp

    Clay B. Thorp

    Director

    May 15, 2025

     

     

     

    /s/ Benjamin R. Yerxa

    Benjamin R. Yerxa

    Director

    May 15, 2025

     

     


    Get the next $CLSD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLSD

    DatePrice TargetRatingAnalyst
    7/18/2025$2.00Buy → Hold
    Stifel
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    7/18/2025Buy → Neutral
    H.C. Wainwright
    8/21/2024$6.00Buy
    Chardan Capital Markets
    6/25/2024$5.00Outperform
    Oppenheimer
    3/11/2022$11.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$19.00 → $9.00Outperform
    Wedbush
    7/29/2021$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLSD
    SEC Filings

    View All

    Clearside Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/14/25 4:05:30 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Clearside Biomedical Inc.

    10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/8/25 4:05:49 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Clearside Biomedical Inc.

    DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/4/25 8:00:10 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    11/4/24 4:15:04 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    6/24/24 4:38:02 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

    - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME). XIPERE is approved for use in the United States, Canada, Australia

    7/23/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

    - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, Ga., July 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced plans to explore a full range of strategic alternat

    7/17/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

    ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the de

    5/21/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Deignan Charles A.

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    1/10/25 4:30:10 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Chong Ngai Hang Victor

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    1/10/25 4:30:07 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clearside Biomedical downgraded by Stifel with a new price target

    Stifel downgraded Clearside Biomedical from Buy to Hold and set a new price target of $2.00

    7/18/25 8:10:27 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Clearside Biomedical from Buy to Neutral

    7/18/25 8:08:24 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Clearside Biomedical from Buy to Neutral

    7/18/25 8:08:24 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Leadership Updates

    Live Leadership Updates

    View All

    Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

    ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, "Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experie

    11/4/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

    ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t

    7/11/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

    ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin

    4/16/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    11/1/23 4:04:12 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    2/14/23 10:29:32 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    2/13/23 12:19:46 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Financials

    Live finance-specific insights

    View All

    Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

    ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid

    5/8/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

    3/27/25 4:05:00 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

    ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca

    3/12/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care